Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SACHIN MAHAVIR SHRIDHARANI

Allopathic & Osteopathic Physicians Plastic Surgery

NPI
1174679807
CMS profile
538963
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$311,028.78

121 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Galderma Laboratories, L.P. $187,866.37 35
ABBVIE INC. $86,097.88 79
REVANCE THERAPEUTICS, INC. $19,057.69 2
MERZ NORTH AMERICA, INC. $15,780.49 2
MOTIVA USA, LLC $2,226.35 3

Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SACHIN MAHAVIR SHRIDHARANI

NPI 1174679807 · CMS profile ID 538963

Allopathic & Osteopathic Physicians / Plastic Surgery

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174679807?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SACHIN MAHAVIR SHRIDHARANI, NPI 1174679807, CMS profile ID 538963. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174679807?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SACHIN MAHAVIR SHRIDHARANI, NPI 1174679807, CMS profile ID 538963. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174679807?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SACHIN MAHAVIR SHRIDHARANI, NPI 1174679807, CMS profile ID 538963, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1174679807?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

121 matching records · $311,028.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 121 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–121 of 121.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $23.3103/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204270133 CMS
ABBVIE INC. $5,456.1003/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204270139 CMS
ABBVIE INC. $457.2903/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204270113 CMS
MOTIVA USA, LLC $53.4703/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250914450 CMS
MOTIVA USA, LLC $116.0703/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250914452 CMS
Galderma Laboratories, L.P. $3,500.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234702505 CMS
ABBVIE INC. $119.1603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204270108 CMS
ABBVIE INC. $2,550.0003/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1204270102 CMS
Galderma Laboratories, L.P. $12,000.0003/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234702501 CMS
Galderma Laboratories, L.P. $11,024.3503/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234702503 CMS
ABBVIE INC. $1,275.0003/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1204270096 CMS
ABBVIE INC. $637.5002/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1204270089 CMS
Galderma Laboratories, L.P. $3,000.0002/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234702499 CMS
ABBVIE INC. $618.7502/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1204270083 CMS
Galderma Laboratories, L.P. $46.5602/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234702495 CMS
Galderma Laboratories, L.P. $40.9702/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234702497 CMS
Galderma Laboratories, L.P. $46.7702/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234702493 CMS
Galderma Laboratories, L.P. $63.2801/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234702489 CMS
Galderma Laboratories, L.P. $109.4501/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234702491 CMS
Galderma Laboratories, L.P. $64.4801/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234702487 CMS
ABBVIE INC. $637.5001/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1204270077 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $156,561.43 165
PY2020 $63,605.24 48
PY2021 $47,087.57 52
PY2022 $197,736.62 122
PY2023 $249,954.14 159
PY2024 $93,134.29 52
PY2025 $311,028.78 121

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $379,505.97 35
PY2024 Recipient $37,500.32 15
PY2024 Principal investigator $187,708.16 8
PY2023 Principal investigator $166,198.92 30
PY2022 Recipient $3,889.17 25
PY2022 Principal investigator $395,409.06 42
PY2021 Recipient $13,550.00 5
PY2021 Principal investigator $498,734.00 25
PY2020 Principal investigator $1,172,155.58 58
PY2019 Recipient $20,006.01 6
PY2019 Principal investigator $22,219.44 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $31,356.26 12/31/2025 Non-covered Recipient Entity
LUXURGERY NYC
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation No dispute reported 06/30/2026 1202533371
Principal investigator 1 ABBVIE INC. $916.68 12/31/2025 Non-covered Recipient Entity
LUXURGERY NYC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202533373
Principal investigator 1 ABBVIE INC. $1,951.95 12/18/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202531320
Principal investigator 1 ABBVIE INC. $4,655.70 12/17/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202531030
Principal investigator 1 ABBVIE INC. $7,409.60 11/20/2025 Non-covered Recipient Entity
LUXURGERY LLC
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202524902
Principal investigator 1 ABBVIE INC. $1,739.10 11/13/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202524209
Principal investigator 1 ABBVIE INC. $6,123.90 11/13/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524211
Principal investigator 1 Galderma Laboratories, L.P. $1,883.00 11/12/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234517494
Principal investigator 1 Galderma Laboratories, L.P. $10,969.20 10/17/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234517273
Principal investigator 1 ABBVIE INC. $11,082.79 10/16/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202517247
Principal investigator 1 ABBVIE INC. $6,040.20 10/15/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516931
Principal investigator 1 ABBVIE INC. $5,362.80 09/19/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202511644
Principal investigator 1 ABBVIE INC. $13,632.30 09/18/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511412
Principal investigator 1 ABBVIE INC. $5,163.00 08/14/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202504831
Principal investigator 1 ABBVIE INC. $7,633.95 08/14/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504909
Principal investigator 1 Galderma Laboratories, L.P. $5,043.60 08/05/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515542
Principal investigator 1 ABBVIE INC. $7,193.50 07/17/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202498662
Principal investigator 1 ABBVIE INC. $24,453.75 07/16/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498400
Principal investigator 1 Galderma Laboratories, L.P. $723.60 07/09/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515249
Principal investigator 1 Galderma Laboratories, L.P. $6,107.40 06/20/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515028
Principal investigator 1 ABBVIE INC. $8,894.70 06/17/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202491737
Principal investigator 1 ABBVIE INC. $16,794.15 06/12/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491121
Principal investigator 1 ABBVIE INC. $7,670.25 05/16/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202485357
Principal investigator 1 ABBVIE INC. $29,425.35 05/16/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485359
Principal investigator 1 Galderma Laboratories, L.P. $7,646.40 05/15/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234514635
Principal investigator 1 ABBVIE INC. $23,401.15 04/17/2025 Non-covered Recipient Entity
LUXURGERY LLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202477372
Principal investigator 1 ABBVIE INC. $23,151.60 04/16/2025 Non-covered Recipient Entity
LUXURGERY LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476897
Principal investigator 1 Galderma Laboratories, L.P. $5,005.80 03/31/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234513951
Principal investigator 1 ABBVIE INC. $21,767.10 03/13/2025 Non-covered Recipient Entity
LUXURGERY LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463657
Principal investigator 1 ABBVIE INC. $9,329.20 03/13/2025 Non-covered Recipient Entity
LUXURGERY LLC
M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202463661
Principal investigator 1 Galderma Laboratories, L.P. $3,655.80 03/03/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234513487
Principal investigator 1 Galderma Laboratories, L.P. $1,992.60 02/14/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234513222
Principal investigator 1 ABBVIE INC. $26,630.70 02/13/2025 Non-covered Recipient Entity
LUXURGERY LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202451262
Principal investigator 1 Galderma Laboratories, L.P. $9,069.29 01/24/2025 Non-covered Recipient Entity
LUXURGERY
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234512680
Principal investigator 1 ABBVIE INC. $25,629.60 01/16/2025 Non-covered Recipient Entity
LUXURGERY LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202439340